Table 2 Rectal cancer patient characteristics
From: Endoglin (CD105) and VEGF as potential angiogenic and dissemination markers for colorectal cancer
Characteristic | Patients (n = 40) | Frequency (%) |
|---|---|---|
Gender | ||
Male | 26 | 65 |
Female | 14 | 35 |
Age (years) | ||
≤ 65 | 15 | 37.5 |
> 65 | 25 | 62.5 |
Tumor site | ||
High rectum (11–15 cm from AM) | 13 | 32.5 |
Medium or low rectum (6–10 cm and 0–5 cm from AM) | 27 | 67.5 |
Colonoscopy biopsy | ||
Adenocarcinoma | 39 | 97.5 |
Polyp | 1 | 2.5 |
Neoadjuvant treatment (radiotherapy plus capecitabine) | ||
Yes | 27 | 67.5 |
No | 13 | 32.5 |
TNM preoperative stage (cTNM) | ||
Less aggressive (polyp, stages 0, I, and II) | 14 | 35 |
More aggressive (stages III and IV) | 26 | 65 |
TNM postoperative stage (pTNM/ypTNM) | ||
Less aggressive (polyp, stages 0, I, and II) | 26 | 65 |
More aggressive (stages III and IV) | 14 | 35 |
Adjuvant treatment (XELOX, oxaliplatin-capecitabine) | ||
Yes | 28 | 70 |
No | 12 | 30 |
Metastasis | ||
Yes | 8 | 20 |
Synchronous | 5 | 12.5 |
Metachronous | 3 | 7.5 |
No | 32 | 80 |
Metastasis location | ||
Liver | 2 | 7.5 |
Lung | 3 | 5 |
Ganglion | 1 | 2.5 |
Other locations | 2 | 5 |
Survival (at the endo of study) | ||
Alive | 36 | 90 |
Died | 4 | 4 |